Abiopharma

🔍 Green Park & Golf Ventures II, LLC (Executive)

Company: Mobia Medical, Inc. (MOBI)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 18,374 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 18,374.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 116,940 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 135,314.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 56,421 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 191,735.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 41,666 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 233,401.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Acquired 477,329 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 477,329.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 45,711 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 523,040.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 32,750 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 555,790.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Acquired 282,122 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 282,122.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Acquired 60,579 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 60,579.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Acquired 9,474 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | shares_owned_after: 70,053.00 | transaction_form_type: 4 | Footnotes: F7, F6
• Acquired 24,506 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 24,506.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Acquired 43,640 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 43,640.00 | transaction_form_type: 4 | Footnotes: F1, F9
• Acquired 6,890 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | shares_owned_after: 50,530.00 | transaction_form_type: 4 | Footnotes: F7, F7
• Sold 6,731 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: false | shares_owned_after: 43,799.00 | transaction_form_type: 4 | Footnotes: F11, F7, F7
• Sold 18,374 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 116,940 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 56,421 shares of Series E-2 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 41,666 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F2
• Sold 477,329 shares of Series E-2 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F4
• Sold 45,711 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F4
• Sold 32,750 shares of Convertible Notes (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F4
• Sold 282,122 shares of Series F Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F5
• Sold 60,579 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F6
• Sold 9,474 shares of Series D Preferred Warrant (Derivative)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F7, F7, F7, F7, F6
• Sold 24,506 shares of Series E-1 Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F8
• Sold 43,640 shares of Series D Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F9
• Sold 6,890 shares of Series D Preferred Warrant (Derivative)
  Date: 2026-05-11 | Code: X | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F7, F7, F7, F7, F7

Footnotes:

• F1: Each share of Series D Preferred Stock, Series F Preferred Stock, Series E-1 Preferred Stock and Series E-2 Preferred Stock converted into Common Stock immediately prior to the completion of the Issuer's initial public offering (the "Offering") pursuant to its terms.
• F2: The securities are held by GPG JCT, LLC ("JCT").
• F3: The Convertible Notes automatically converted into Common Stock immediately prior to the closing of the Offering. The conversion price is the lower of (a) 80% of the Offering price per share and (b) the valuation of the Issuer immediately prior to the closing of the Offering divided by the number of fully diluted shares of capital stock (on an as-converted basis) outstanding immediately prior to Offering, excluding the Convertible Notes.
• F4: The securities are held by GPG MTI 22, LLC ("MTI 22").
• F5: The securities are held by GPG MTI 25, LLC ("MTI 25").
• F6: The securities are held by GPG MTI 3-17 Investment, LLC ("MTI 3-17").
• F7: Common stock issued upon exercise of warrant to purchase Series D Preferred Stock. The warrants are currently exercisable and have an exercise price of $4.207 per share. Unless exercised earlier, the warrants will expire on May 25, 2033.
• F8: The securities are held by GPG PHL, LLC ("PHL").
• F9: The securities are held by GPG RM Investment, LLC ("RM").
• F10: Green Park & Golf Ventures II, LLC ("GPG Ventures II") is the managing member of each of JCT, MTI 22, MTI 25, MTI 3-17, PHL, and RM. Clay M. Heighten, MD, Carl D. Soderstrom and Gilbert G. Garcia II are managers of GPG Ventures II and share voting and dispositive power with respect to the shares held by each of JCT, MTI 22, MTI 25, MTI 3-17, PHL, and RM., and as a result may be deemed to beneficially own such securities.
• F11: RM paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 6,731 shares of Common Stock to pay the exercise price and issuing to the reporting person the remaining 159 shares of Common Stock.
• REMARKS: This Form 4 is the second of five Forms 4 filed relating to the same event. Combined, the five Forms 4 report the holdings for the following reporting persons: Green Park & Golf Ventures II, LLC, Clay M. Heighten, MD, Carl D. Soderstrom, Gilbert G. Garcia II, GPG BFH, LLC, GPG Charles & Potomac, LLC, GPG Dais, LLC, GPG GR, LLC, GPG Healthcare Opportunities Fund II, LLC, GPG Healthcare Opportunities Fund, LLC, GPG JCT, LLC, GPG MTI 22, LLC, GPG MTI 25, LLC, GPG MOBI, LLC, GPG MTI 3-17 Investment, LLC, GPG PHL, LLC, GPG RM Investment, LLC, GPG SC, LLC, GPG WG, LLC, GPG MTIF, LLC, Micro TI Investment 2, LLC, Micro TI Investment, LLC, MTI 20 Investment, LLC, MTI 2015 Investment, LLC, HTX MCT1 0320 Investment, LLC, HTX MCT2 0221 Investment, LLC, HTX MCT3 0322 Investment, LLC, HTX MCT4 0226 Investment, LLC and Green Park & Golf Ventures - Houston, LLC. The Form 4 has been split into five filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons.